Skip to contentP
Panacea Life Sciences Holdings, Inc.
P
PLSHPanacea Life Sciences Holdings, Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$645.95K$645.95Kderivedno prior Q4 2020 on file Net Income-$2.09M-$2.09MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Panacea Life Sciences Holdings, Inc. · CIK 1552189 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$10,412— Operating Incomederived-$2,148,023— Operating Cash Flowderived-$1,229,887N/M Free Cash Flowderived-$1,220,436N/M Margins · derivedGross margin1.6%
Operating margin-332.5%
Net margin-323.6%
ended Dec 31, 2021 · filed Mar 31, 2022 · 90 d after period end